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ABSTRACT
JOSHUA DANIEL DOLSEN: O-GlcNAcylation of HIF-1α Protein in Human Breast
Cancer Cells
Cancer is an insidious disease that, if not caught in time, can cause devastating
effects on the human body, especially if it metastasizes. It is important to note that each
cancer behaves and develops differently based on its location in the body and the cellular
characteristics constitute the instance of the disease. However, the development of cancer
can universally be characterized by the acquisition of different hallmark abilities that
promote disease progression. Proteins known as hypoxia-inducible factors (HIFs) can
influence progression through these hallmarks, but primarily provides cancer cells with the
ability to alter its metabolism to survive and further progress in hypoxic conditions, which
are common intratumorally. The HIF transcription factors are composed of two subunits,
an ‘α’-subunit that is oxygen-regulated and a constitutively expressed ‘β’-subunit.
Posttranslational modifications are a common form of regulation among cell types.
Specifically, enhanced O-GlcNAcylation, the addition of O-linked β-N-acetylglucosamine
(O-GlcNAc), has been observed to have implications in the progression of diseases,
including breast cancer. The purpose of this research is to detect O-GlcNAcylation of HIF1α protein, using the triple negative breast cancer MDA-MB-321-derived (MDA-MB-231
BoM) bone-specific organotropic subclone as an in vitro model.
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Introduction/Background
Cancer is among one of one of the most common causes of death in some countries
and has become an increasingly popular area of research. This disease does not
discriminate and presents itself in many different forms throughout the body. Cancer is an
umbrella term used to describe a variable set of diseases that is characterized by unusual,
uncontrolled cell proliferation, that often spreads to neighboring tissues as it manifests. In
cancerous cells, the cellular life cycle, replication, and apoptosis, are altered, which results
in this abnormal, uncontrolled cell growth that frequently allows for the formation of
tumors. Cancer cells arise from pre-existing, healthy cells (Hanahan and Weinberg, 2011).
Healthy cells recognize and respond accordingly to cell-to-cell signaling, and
environmental cues that allow these cells to dictate their replication and life cycle in order
to mature, but also not cause damage. In contrast, cancerous cells disobey many of these
signals and do not differentiate into cells that provide a specialized physiological function.
Consequently, this can result in continuous replication of abnormal cells that often
accumulate genomic mutations. Normal, healthy cells would be able to repair such damage
or undergo apoptosis if the damage was permanent, but cancerous cells lack this ability. In
contrast to normal cells, that usually reside within the tissue they are physiologically
specialized for, cancerous cells are likely to detach and systematically travel. The
cancerous cells that do travel throughout the body increases the severity of the disease,
especially if a mass of cells leaves its area of origin and continues to replicate and develop
in a process called metastasis. These primary changes in cellular characteristics are the
result of the aggregation of mutations which either cause an overexpression of tumorpromoting oncogenes, or a disabling or under expression of tumor suppressing genes
1

(Hanahan and Weinberg, 2011). Simply stated, the emergence of cancer is due to the
accumulation of mutations.
A solid foundation for understanding the biology of cancer has been established by
what Hanahan and Weinberg call the Hallmarks of Cancer. These hallmarks describe ten
biologically, particular and distinctive capabilities that allow for cancer cells to form
tumors, grow these tumors, and metastasize. These capabilities are acquired during the
multistep development of tumors and include the major abilities of proliferative signaling,
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing
angiogenesis, and activating invasion and metastasis (Hanahan and Weinberg, 2011). Each
can emerge independently from each other, but one or more hallmarks can induce the birth
of another through its impact on tumor cells. In particular, one of the most foundational
characteristics of cancerous cells is perpetuation of chronic proliferation. This is partially
achieved either by the disabling of tumor suppressor genes, and unresponsiveness to
contact inhibition, which can result in evading growth suppressing factors (Hanahan and
Weinberg, 2011). Cancer cells, in opposition to normal conditions, can also deregulate the
production and release of growth-promoting signals that dictate progression of cellular
growth, becoming unrestricted by normal cell limitations and free from reliance on external
growth factors (Hanahan and Weinberg, 2011). This abnormality among these cells allows
for self-sufficiency by utilizing autocrine signaling, indelibly activating proliferative
pathways, and deactivating negative feedback systems (Thermofisher, 2015). By acquiring
the ability of self-proliferative signaling, and evading repressors of cell growth, tumor cells
can obtain this unique ability of uncontrolled replication. Underlying these hallmarks,
genome instability, chronic inflammation, reprogramming of cellular metabolism, and
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evasion of the immune system collectively drive cancer progression (Thermofisher, 2015)
(Hanahan and Weinberg, 2011).
Cancer may develop anywhere in the body and is capable of forming solid tumor
masses, or tumors that affect blood cells. In general, there are two ways to classify cancer:
by tissue type of origin or histologic characteristics of the cancer and by primary location,
where it first developed (National Cancer Institute, 2019). Cancer cells resemble the cells
of tissues from which they originate; breast cancer will resemble breast tissue. Breast
cancers can emerge in various parts of the breast. Most arise in the ducts that move milk
from the breast lobules to the nipple, but some cancers form in the milk-producing lobules
or rarely in the connective tissue (American Cancer Society, 2019) (Mayo Clinic, 2018).
Initially, diagnosis of breast cancer is done through breast exams, either by touch or
mammogram, or breast ultrasound. If cancer is suspected, a biopsy of the breast tissue
containing the cells from the suspicious area is analyzed to confirm if they are cancerous,
and if so, reveal cell-specific traits (Mayo Clinic, 2019). All breast cancers are not identical
and have unique characteristics that help provide insight on behavior, course of treatment,
and prognosis. Certain cell surface receptor types, particularly presence of receptors for
estrogen (ER-positive) and progesterone (PR-positive) used for growth stimulation,
indicate sensitivity to these hormones; treatment includes endocrine therapy (Mayo Clinic,
2018). Another specific characteristic is the expression of the human epidermal growth
factor receptor 2 (HER2) protein, which provides another therapeutic target. In contrast to
cells that express these receptor types, triple negative breast cancer (TNBC) cells lack
estrogen, progesterone, and HER2 receptors and are much more difficult to treat (Zhou et
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al, 2018). Lacking these receptors results in greater difficulty when treating this specific
type of breast cancer cell due to reduction in number of molecular targets.
Cancers are also described based on their stage of development, denoted stage 0
through 4. Knowing the stage at which the cancer has developed is a vital tool in treatment.
This knowledge also allows for the development of more effective treatment methods
(Mayo Clinic, 2018). Breast cancer progresses through these 4 stages, which respectively
correlate to severity and invasiveness. Stage 0 breast cancer includes non-invasive,
localized masses that show no evidence of invasion to neighboring tissues. Cancer stages
1 through 3 involve invasive cancers that respectively spread to the neighboring lymph
nodes. If cancerous masses are able to further develop, some cancers may reach stage 4.
This final stage of cancer development occurs when invasive breast cancer spreads beyond
breast tissue and nearby lymph nodes to different parts of the body (Mayo Clinic, 2018).
Stage 4 cancer is commonly called advanced or metastasized cancer, and breast tumors at
this stage usually spread to the brain, bone, lung, and liver (Zhou et al, 2018). Over 90%
of all deaths due to breast cancer is due to metastasis (Gilkes and Semenza, 2013) (Muz et
al, 2015). Due to the type of tissue breast cancer usually emerges in, approximately 0.1%
of men will develop this disease over their lifetime based annual incidence rates (American
Cancer Society, 2019). The 99.9% of other cases occur in females. According to the Breast
Cancer Research Foundation, breast cancer is the most common cancer among American
women after skin cancer and represents one in four of all cancers among women (Breast
Cancer Research Foundation, 2018). Due to the increasing severity and invasiveness of
breast cancer respective to its stage, and how common the disease is in women, early
detection is imperative.
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As cancers develop and form masses a complex microenvironment forms at the
tumor site. The tumor microenvironment (TME) has become recognized as a major
promoter for tumorigenesis and disease progression, as well as a useful tool to determine
response to treatment (Soysal et al, 2015) (Wang et al 2017). The tumor microenvironment
is composed of the interactions between the tumor and the adjacent tissues, which
encompasses multiple cell types, including immune cells, blood vessels, inflammatory
cells, the extracellular matrix (ECM), and cell-signaling molecules (Chen et al, 2015).
Normal cells involved in the TME of breast cancer include fibroblasts, leukocytes,
adipocytes, and myoepithelial and endothelial cells (Soysal et al, 2015). These interactions
between the tumor and the surrounding components affects how the tumor grows and
develops by providing the cancerous mass with different tools to progress in severity.
In particular, the tumor’s response to inflammation is a critical factor in cancer
development. When the immune system recognizes a tumor as antigenic, the immune
response of nearby fibroblasts and immune cells, as well as the ECM is similar to that of
dealing with a wound. This includes, pro-inflammatory signals, aiding in angiogenesis,
preventing apoptosis, and accelerating the cell cycle, which in union highly promotes
tumorigenesis (TME role). Inflammation in the TME is the result of this network of
signaling from cells in the area. Dying cells that undergo necrosis also release proinflammatory signals into the surrounding tissue microenvironment that further recruits
inflammatory cells and immune cells specialized for clearing necrotic debris (Hanahan and
Weinberg, 2011). Sentinel immune cells, recruited leukocytes and even tumor cells, are
also capable of releasing pro-inflammatory cytokines; soluble proteins that mediate cellto-cell communication (Chen et al, 2015). Cytokines are synthesized and released to
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combat infection or tissue damage; however, these signaling molecules can have tumor
promoting effects. Local fibroblasts and endothelial cells synthesize and release these
proteins in response to inflammation. When fibroblasts remain activated, their signaling
continues to work with other molecular pathways to promote neoplasm initiation in the
TME. These activated fibroblasts are termed cancer-associated fibroblasts (CAFs) and are
the most abundant cells in the breast cancer stroma (Soysal et al, 2015) (Wang et al 2017).
Aside from recruiting immune cells, CAFs have an essential role in the promotion of
metastasis and development of cancer through remodeling the ECM by inducing
angiogenesis and directly stimulating cancer through hematopoietic growth factor (HGF),
transforming growth factor beta (TGF- β), and platelet-derived-growth factor (Wang et al
2017). This differs from normal fibroblasts, which typically combat cancer development.
Angiogenesis, another hallmark of cancer development, is the formation of new
blood vessels. In normal conditions, angiogenesis plays a role in wound healing and the
female reproductive cycle and is regulated. In contrast to normal physiological conditions,
during tumor progression an angiogenic switch is almost always activated and remains on,
which results in continuous sprouting of new vessels that helps sustain tumor growth
(Wang et al 2017). Similar to normal tissues, tumors require oxygen and nutrients from
blood supply, and the ability to remove wastes and carbon dioxide; the tumor-associated
neovasculature formed fulfills this need (Hanahan and Weinberg, 2011). Cancer-associated
fibroblasts may promote tumor growth and invasion through release of fibroblast growth
factor 2 (FGF2), and vascular endothelial growth factor (VEGF) into the TME. Proangiogenic signals, like VEGF, are also secreted by cancer cells and many other cell types
involved in the TME, including macrophages, platelets, adipose cells and keratinocytes
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(Chen et al, 2015) (Wang et al, 2017). There are over a dozen proteins known to have
angiogenic promoting and inhibiting effects and pro-angiogenic protein expression levels
in cancer cells correspond to aggressiveness (Nishida et al, 2006). Induction of
angiogenesis occurs early during the multi-stage development of invasive cancers, and
once activated tumors display diverse patterns of neovascularization; the new blood vessels
are abnormally leaky and inefficiently perfused in comparison to normal vasculature. As a
result of these unusual and incomplete blood vessels, blood supply varies throughout the
tumor and immune surveillance of the tumor is hindered, which also assists in evasion of
host immune response (Hanahan and Weinberg, 2011). In addition, these newly formed
blood vessels also provide cancer cells a pathway into systemic circulation which
designates angiogenesis as a vital step in the development of metastatic cancer.
Another critical component of the tumor microenvironment that greatly affects
cancer progression is tumor hypoxia. Hypoxia occurs when tumor cells are exposed to a
non-physiological level of oxygen tension and is a common factor in a majority of
cancerous tumors (Muz et al, 2015). In normal conditions, tissues are in a state of normoxia
if no complications are present. Due to structural and functional abnormalities of newly
formed tumor vessels the diffusion of oxygen is limited, resulting in varying concentrations
of oxygen throughout the tumor; diffusion of oxygen decreases as distance from the blood
vessel increases (Gilkes and Semenza, 2013) (Liu et al, 2015). Other factors that can result
in hypoxia include disease or treatment associated anemic reduction of oxygen transport.
Reduction in intratumoral oxygen availability consequently suppresses tumor growth,
slowing cell proliferation, which frequently leads to regions of necrosis in solid tumors.
However, hypoxia can also promote tumorigenesis by altering expression of hypoxia-
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associated genes, changes in metabolism, and promotion of angiogenesis (Semenza, 2015).
Given than there are varying levels of oxygen concentration throughout the TME, cancer
cells throughout the tumor behave differently to decreased oxygenation. Normal cells in
stressful conditions, like hypoxia, can activate autophagy, a metabolic and apoptotic
adaption where intracellular organelles and proteins are captured, degraded and recycled
in order to decrease oxidative metabolism and maintain homeostasis. Autophagy allows
for the survival in short-term hypoxic conditions, but also has implications in the
development of cancer. In some cases, this process acts as a suppressor to tumor growth,
but in most contexts, tumorigenesis is promoted. Deficiencies in the microenvironment, as
well as increased metabolic and biosynthetic demands, are likely causes of dependency on
autophagy (Degenhardt et al, 2006) (Thermofisher, 2015). Within hypoxic tumor regions,
basal autophagy is upregulated because it is vital for cell survival (Degenhardt et al, 2006).
In breast cancer it is common to find Intratumoral hypoxia and approximately 25%-40%
of invasive breast cancers exhibit hypoxic regions. Both hypoxic conditions and autophagy
in cancer cells are driving TME conditions that are associated with more aggressive tumor
phenotypes and increased risk of metastasis (Lundgren et al, 2007) (Muz et al, 2015)
(Semenza, 2015).
Tumor cells that are exposed to hypoxic conditions for longer periods of time are
associated with a number of other characteristics that further the development of a more
insidious disease. Prolonged exposure to low oxygen concentration in cancer cells are
connected to increased genomic instability and mutagenesis, that potentially results from a
higher frequency of DNA breaks, and an aggregation of DNA replication errors from
hindered DNA repair systems. Due to higher mutation rates and rapid p53-dependent
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apoptosis, an environment that selects for cells that can survive longer in these stressful
conditions are selected for, especially after these cells experience reoxygenation (Muz et
al, 2015). As unfit tumor cells and normal cells die off in the TME, the cells that do survive
cycling hypoxia with sporadic reoxygenation periods are often more fit for proliferation
and metastasis, further promoting cancer development, as well as more resistant to
chemotherapy and radiation treatment (Liu et al, 2015).
Hypoxic stress also influences changes in gene expression in both normal cells and
cancer cells similarly apart from some key differences. In cancerous cells, this
environmental pressure alters a number of complex intracellular signaling pathways
involved in proliferation, survival, apoptosis, metabolism, migration, extravasation, and
inflammation. In human cells, oxygen acts at the terminal electron acceptor in the process
of oxidative phosphorylation and an adequate amount is needed in order to generate ATP.
In particular, increasing the activity of hypoxia-inducible factors (HIFs) is a common
response by both normal cells and cancer cells to decreased oxygen levels in order to
regulate oxygen consumption among some of their other effects (Semenza, 2015).
Adaptation to hypoxic conditions occurs through two transcription factors, HIF-1 and HIF2, which regulate the expression of over 1000 target genes (Semenza, 2012). Notably, HIF1 has been found to have a pivotal role in cancer cell adaptation to hypoxia and found to
be elevated in solid tumors of the brain, colon, pancreas and breast cancers (Liu et al, 2015).
HIF-1 is a heteromeric-dimeric transcription factor that consists of an oxygen regulated
HIF-1α subunit and a constitutively expressed HIF-1β subunit (Wang et al, 1995). The
HIF-1β is also known as the aryl hydrocarbon receptor nuclear translocator (ARNT), and
both subunits contain basic-helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) domains
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that partake in DNA binding and dimerization, respectively; both belong to the bHLH-PAS
protein superfamily (Liu et al, 2015) (Wang et al, 1995). HIF-1α contains an oxygendependent degradation (ODD) domain that regulates the stability and activity of the
protein. This is achieved through hydroxylation by prolyl hydroxylase proteins of specific
proline and asparagine residues in the presence of oxygen. Hydroxylation of the ODD is
needed in order for the binding and ubiquitination by the von Hippel-Lindau protein, which
targets the HIF-1α protein for degradation in the proteasome (Liu et al, 2015). Under
hypoxic conditions, this hydroxylation is inhibited due to decreased levels of oxygen,
which results in stabilization of HIF-1α, increased interaction with its co-activators, and its
accumulation (Liu et al, 2015). As HIF-1α levels increase, the alpha and beta subunits
hetero-dimerize leading to increased levels of HIF-1, resulting in increased transcription of
HIF-1 associated genes. Since HIF-1β is normally produced in physiological conditions,
HIF-1α can be considered the hypoxic-response element.
Numerous HIF-1 target genes play a major role in many essential aspects of breast
cancer biology. At diagnosis, high levels of HIF-1α are indicators of early relapse and
metastasis, as well as related to poor clinical outcomes regarding human breast cancer
patients (Liu et al, 2015). These target genes of HIF-1 are also upregulated in the TNBC
subgroup (Gilkes and Semenza, 2013). Overexpression of these genes have crucial activity
in cancer hallmarks, including angiogenesis, metabolic reprogramming, resisting
apoptosis, invasion, and metastasis (Semenza, 2012). HIF-1 has emerged as a major target
molecule of cancer therapy because it mediates many different mechanisms in cancer cells
that are involved in metastasis and cancer severity. Understanding the molecular and
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cellular mechanisms that fundamentally lead to metastasis, especially those in HIF-1 can
be helpful in developing accurate prognoses and new treatment methods.
Essentially, the initiation of metastasis consists of epithelial cells detaching from
the primary tumor, adhering to and invading the surrounding stroma. The detachment of
epithelial cells from primary tumors is thought of as the first step in metastasis and these
cells undergo a transition process that resembles epithelial-mesenchymal transition (EMT)
(Liu et al, 2015). HIF-1 upregulates EMT-associated transcription factors, or repressors, as
well as activates signaling pathways associated with EMT that result in these cells losing
epithelial phenotypical characteristics and obtaining mesenchymal cell-associated
characteristics (Liu et al, 2015). Cellular and molecular characteristics such as absence of
cell-to-cell adhesion, upregulation of vimentin, a mesenchymal protein, alteration of the
cytoskeleton to promote flexibility, and increased motility are provoked by HIF-1 activity
in tumor cells (Liu et al, 2015). In hypoxic microenvironments, these acquired
characteristics promote the invasive ability of breast cancer cells that allow for metastasis.
Following invasion of the stroma by these cells that underwent EMT, invasion of
the connective tissue and intravasation into the bloodstream takes place if the complex
process of metastasis continues. The two routes that are utilized by cancer cells to gain
access to physiological circulation are lymphatic vessels and blood vessels (Gilkes and
Semenza, 2013). To acquire access to the lymph or blood vessels, HIF-1 activates the
transcription of genes that encode for proteases. Degradation or remodeling of the
extracellular matrix within the primary tissue and at distant sites of metastasis are vital
factors that allow for invasion and intravasation (Semenza, 2012). Specifically, proteases,
termed matrix metalloproteinases (MMPs), are zinc-dependent endo-peptidases that
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degrade many components of the extracellular matrix and surrounding basal membrane;
MMP-2 and MMP-9 proteases are positively correlated to higher instance of breast cancer
metastasis (Liu et al, 2015). Many studies suggest that HIF-1 further promotes the
expression levels of MMP-2 and MMP-9 (Liu et al, 2015). HIF-1 also elicits the production
of permeability factors VEGF and angiopoietin-2 (ANGPT2) that aid in the ability to
intravasate, or pass into, the blood or lymph vessel (Semenza, 2012). Both VEGF and
ANGPT2 induce angiogenesis and vascular modeling. Once cancer cells gain access to
circulatory vessels, the ability to migrate to other tissues is enabled. If these cells are able
to leave blood or lymph vessels, the disease itself may establish itself in other tissues and
wreak havoc on the body.
Cancer cells that have entered circulation must leave, or extravasate from, the
vessel in order to establish secondary tumors. Approximately less than 0.1% of cancer cells
that enter circulation are able to produce a metastatic lesion (Liu et al, 2015). Traveling to
distant tissues where cancer cells can then extravasate from the bloodstream is considered
a limiting step in the metastasis process. This step is limiting because cells must first adhere
to endothelial cells (ECs) in the vasculature, then disrupt the close interactions between
these cells to extravasate into the distal tissue (Liu et al, 2015). A study that investigated
metastasis of breast cancer to lung tissue revealed that HIF-1 promoted extravasation
(Zhang et al, 2011). It was also found that HIF-1 induces the production of angiopoietinlike 4 (ANGPTL4). Expression of ANGPTL4 in cancerous cells results in disruption of the
vascular junctions between ECs, which increases the permeability of lung capillaries.
Because of this, extravasation of cancer cells is facilitated into lung tissue, a common site
of breast cancer metastasis (Padua et al, 2008). The TNBC cells that overexpress the HIF-
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1 protein, also show EC monolayer adherence in a HIF-1-dependent form. A direct target
of HIF-1 transcription, L1 cell adhesion molecule (L1CAM) is a cell surface protein that
plays a key role in mediating cell-cell adherence through homophilic and heterophilic
interactions with integrins, neuropilin 1, or the CD24 cell surface receptor (Semenza,
2012). Cancer cells that overexpressed L1CAM promoted adhesion of these cells to EC
monolayers in vitro and revealed an increase in the number of cancerous cells that
extravasated into lung tissue in mice (Zhang et al, 2011). These products of HIF-1 induced
transcription, allow for the promotion of extravasation, providing cancer cells with the
ability to invade distant tissues where they can establish metastatic sites.
An emerging hallmark of cancer is reprogramming of cellular metabolism.
Compared to healthy cells, cancer cells exhibit a higher energy demand due to rapid,
increased cell proliferation, and varying available oxygen levels. Reprogramming
metabolism is an essential biological process that provides a selective advantage for
survival and growth by utilizing conventional metabolic pathways to generate energy and
biosynthetic precursors, as well as maintain redox balance; Hypoxic conditions are capable
of inducing metabolic alterations in tumor cells (Chen et al, 2015) (Muz et al, 2015).
Normal cells under aerobic conditions, use glycolysis to break down glucose into pyruvate
in the cytosol, which is further processed to CO2 in the mitochondria. When a cell is unable
to obtain adequate amounts of oxygen for aerobic respiration, cells favor glycolysis in order
to meet energy needs and very little mitochondrial oxygen-dependent activity takes place.
Cancer cells, even in the presence of oxygen, can alter their metabolic activity, and
consequently their production of energy, by limiting their glucose energy metabolism
mostly to glycolysis. This state of cellular metabolism has been termed “aerobic
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glycolysis” (Hanahan and Weinberg, 2011). The process of glycolysis alone is not
sufficient for cellular survival, and cancer cells must make up for an approximate 18-fold
ATP deficit afforded by glycolysis relative to oxidative phosphorylation (Hanahan and
Weinberg, 2011). The hypoxia response system plays a key role in promoting the metabolic
changes of cancer cells and acts pleiotropically to compensate for the loss of energy from
mitochondrial function. Specifically, HIF-1 activity can upregulate the biosynthesis of
glucose transporters to increase glucose uptake and glycolytic enzymes (Muz et al, 2015).
Cancer cells also take advantage of glycolytic variability, which is also affected by HIF-1
transcriptional activity. Other metabolic sources such as acetyl-CoEnzyme A, from fatty
acid synthesis, and glutamine are utilized by cancer cells to combat hypoxic conditions
(Hanahan and Weinberg, 2011).
The HIF-1 protein is considered a master regulator of oxygen homeostasis and
cancer development due to the transcriptional effects it produces. However, like any
protein, the HIF subunits, specifically HIF-1α, can be subjected to post-translational
modification (PTM) (Keith et al, 2011). In general, a protein can be modified at any time
during a cell’s life cycle, but most PTM occurs shortly after modification. Various types
of PTMs include phosphorylation, glycosylation, ubiquitination, S-nitrosylation,
methylation, N-acetylation, lipidation, and proteolysis to name a few (Thermofisher, 2019).
In order to achieve responsiveness to hypoxic conditions on a molecular level, an intricate
and interlinked biochemical system involving both short-term modifications and reactions
(no change in gene expression) and corresponding long-term alterations, such as changes
in gene expression is integrated by cells (Semenza, 2017). These short-term responses can
include changes in enzymatic activity that can regulate transcription factors by
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posttranslational signaling events. Interestingly enough, the regulation of the HIF-1α
protein is not impacted by hypoxia alone. These proteins also respond to various stressors,
growth and coagulation factors, cytokines, hormones, each with different protein kinase
regulated pathways, under normoxia (Semenza, 2017). As mentioned before, two bHLHPAS protein subunits form heterodimeric HIFs in hypoxic conditions (Wang et al, 1995).
In terms of HIF regulated genes, response to hypoxia is highly dependent on the α subunits
of HIFs (Keith et al, 2011). Thus, PTM of the HIF-1α subunit can yield differential effects
on cellular functions.
Many proteins that result in HIF-1α PTM regulate HIF-1 activity by either
promoting or inhibiting interactions of HIF-1α with other proteins. Aside from
hydroxylation, which is involved in HIF-1α degradation, the protein subunit is also
subjected to an array of different oxygen-independent PTMs (Semenza, 2017). A vital
PTM for protein activity and stability is phosphorylation. The phosphorylation of the HIF1α subunit can occur by direct or indirect kinase activity, but the overall extent to which
this affects HIF-1 transcription varies based on the signal, cell-type, or tissue (Kietzmann
et al, 2016). The PI3k/PKB (Akt) pathway is a major signaling node that is well known in
tumorigenesis and can result in the indirect phosphorylation of the HIF-1α subunit
(Thermofisher, 2015)) (Keith et al, 2011). One target of PKB(Akt) is glycogen synthase
kinase-3 (GSK3), which can directly phosphorylate HIF-1α, inhibiting its activity.
Phosphorylation of HIF-1α by GSK3 leads to interaction with F-box and WD protein
(Fbw7) and Ubiquitin specific protease 28 (USP28) which systematically degrades the
HIF-1α subunit (Keith et al, 2011). Yet, if GSK3 is phosphorylated by PKB(Atk), then
HIF-1α remains unrestrained by its effects.
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Another PTM that occurs to the HIF-1α protein that has drawn recent attention is
O-Linked β-D-N-acetylglucosamine (O-GlcNAc) modification, or O-GlcNAcylation. OGlcNAc modification is involved in many crucial biological processes including
transcription, translation, signal transduction and proteasomal degradation and has been
found to be directly linked to pathological progression of chronic diseases, one of which is
cancer (Ma and Hart, 2017). Whereas the glycosylation of proteins occurs between Asnlinked (N-linked) or Ser/Thr-linked (‘mucin-type’ O-linked) cell surface and secreted
proteins, O-GlcNAcylation is the covalent attachment of β-D-N-acetylglucosamine to the
hydroxyl group on serine or threonine residues. This modification also almost solely occurs
to proteins that are localized in the nucleus, mitochondria, and cytoplasm. Two enzymes,
O-GlcNAc transferase (OGT) and β-D-N-acetylglucosaminidase (O-GlcNAcase), control
this modification by addition and removal of the O-GlcNAc moiety, respectively. This
allows for the reversibility and dynamicity of the process (Ma and Hart, 2014). In addition,
O-GlcNAcylation can interact with other PTMs, including competitive or reciprocal
activity with phosphorylation, and has been found to have implications in breast cancer
patient outcomes (Ferrer et al 2014).
The importance of investigating O-GlcNAc modification lies within its effects on
cancer cells and the influences it has in the progression of the disease. Although the
mechanism that results in elevated O-GlcNAcylation is not completely understood, the
elevated levels of OGT have been observed in breast, prostate, and lung cancer. Decreased
levels of OGA have been seen in breast and colon cancers as well (Ferrer et al 2014). Breast
cancer cells containing high HIF-1α levels were observed to have had a heightened
occurrence of O-GlcNAcylation with elevated OGT levels. Lower levels of OGA in these
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cells also correlated with poor patient outcome. The process of O-GlcNAcylation regulates
metabolic reprogramming in cancer cells through the regulation of HIF-1α. Both OGT and
O-GlcNacylation are suggested to play key roles in maintenance of aerobic glycolysis, by
increasing HIF-1α stabilization and promoting aerobic glycolysis in a feed-forward
mechanism. Elevation of this PTM was also observed to protect breast cancer cells from
endoplasmic reticulum stress-mediated apoptosis. The process of O-GlcNAc modification
also competes with HIF-1α phosphorylation, which affects GSK3/Fbw7/USP28-dependent
degradation, allowing for continuation of its transcriptional effects on cancer cells (Ferrer
et al 2014) (Ma and Hart, 2014). Due to its influence on multiple hallmarks of cancer, OGlcNacylation has proven to be a promising therapeutic target that can effectively combat
cancers that benefit from it.
Over the span of about 30 years, there have been a number of approaches that have
been developed for O-GlcNAcylated protein analysis. Recently, mass spectroscopy (mass
spec) has emerged as one alternative to detect this modification. In contrast to biochemical
detection methods, such as galactosyltransferase-catalyzed labeling followed by
autoradiography or immunoblotting with specific antibodies, mass spec has provided a
unique capacity for the deduction of O-GlcNAc modification in proteins in a site-specific
and semi-quantitative manner (Ma and Hart, 2017). There have been many methods that
have been applied to the detection of this modification, each using alternative
fragmentation methods. Three of these methods include collision-induced fragmentation
(CID), higher energy collision dissociation (HCD), and electron transfer dissociation
(ETD). Mass Spectrometry-based identification is an especially powerful tool, but it cannot
independently differentiate between O-GlcNAc and O-GalNAc without highly specific
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approaches, such as labeling techniques (e.g., antibodies specific for the molecule). In order
to confirm the status of specific modifications on proteins, techniques such as Western
blotting can be used as a confirmation tool (Ma and Hart, 2017).

18

Materials and Methods

Cell Culture/Compound Treatment
Human breast tumor cell line MDA-MB-231-derived subclone BoM1833 (BoM,
bone metastatic, Massagué, 2003) cells, developed by the Massagué group at Memorial
Sloan Kettering Cancer Center (New York City, NY), were maintained in RPMI1640
medium (GIBCO) supplemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone) and
0.5% penicillin/streptomycin (p/s) (equivalent to 50 units mL-1 and 50 µg mL−1,
respectively) (Life Technologies) in a humidified environment at 37 °C under 5%
CO2/95% Air. The cells were grown on 10 cm tissue culture plates (USA Scientific). To
isolate nuclear extracts, BoM cells were plated at the density of 10 x 106 cells/plate onto
10 cm plates. After overnight incubation, 1,10-phenanthroline (Phen) (Sigma Aldrich) was
added to the cells in a volume of 10 μL (10 mM stock solution in DMSO)/plate to achieve
the final concentration of 10 μM (7 plates), and O-(2-acetamido-2-deoxy-Dglucopyranosylidenamino)-N phenylcarbamate (PUGNAc) (Sigma Aldrich) in a volume
of 30 μL (10 mM stock solution in DMSO)/plate to achieve the final concentration of 30
μM (7 plates).
Following 4-hour incubation of the compounds with the BoM Cells, aspiration of
the conditioned media then took place, and the plate was washed once with cold 1x
Dulbecco’s Phosphate Buffered Saline (DBPS), diluted from 10x DPBS (Sigma Aldrich
D1408). Subsequent detachment of the cells was accomplished by the addition of
0.9mL/plate of 0.25% trypsin ethylenediaminetetraacetic acid (Trypsin-EDTA) solution
(Gibco 25200-056), at 37 °C for five minutes. The trypsin reaction was stopped with the
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addition of 10 mL 10% FBS RPMI1640 Media. The cell suspension was transferred to a
15 mL centrifuge tube, and the pellet was collected after centrifugation at 500 rpm for five
minutes at room temperature.

Cytoplasmic and Nuclear Extract Preparation:
The pellet was washed once with 10 mL cold 1x DPBS and collected by
centrifugation at 500 rpm for five minutes. The cell pellet was then resuspended in 1x
DPBS, transferred to a 1.5 mL microcentrifuge tube, and pelleted by centrifugation at 800
rpm (100 x g) for three minutes. The supernatant was removed, leaving the cell pellet as
dry as possible in the microcentrifuge tube. Ice-cold cytoplasmic extract reagent (CER) I
(950 μL) was then added to the cell pellet and vortexed for 15 seconds. Incubation of the
tube on ice for 10 minutes followed. After chilling, 55 μL of CER II was added to the tube
and vortexed for five seconds (16,000 x g). The cell lysate was centrifuged at 16,000 x g
for five minutes at 4 °C. The supernatant and pellet produced from this step are the
cytoplasmic extract and the nuclei pellet, respectively.
Immediately after, the supernatant was transferred to a pre-chilled tube, and the
tube containing the pellet was supplemented with ice-cold nuclear extract reagent (NER)
(475 μL) to lyse the nuclei. The nuclear lysate was then vortexed for 15 seconds and chilled
for 10 minutes for a total time of 40 minutes; four cycles of centrifugation (16,000 x g) for
10 minutes. The supernatant (nuclear extract sample) was transferred to a new tube. Both
nuclear and cytoplasmic extract samples were aliquoted to new tubes respective to the
following: NE 5 μL(1x); 15 μL (2x); ~150 μL (1x); remaining NE ~350 μL and CE 5
μL(1x); 20 μL (1x); 100 μL (1x); 200 μL (2x); remaining CE~500 μL. The production of
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cellular extracts from Phen and PUGNAc BoM cells yielded 4 distinct extracts: NE+Phen,
NE+PUGNAc, CE+Phen, and CE+PUGNAc.

Protein Concentration and Quantification:
Analysis and standard comparison of BoM cytoplasmic and nuclear extracts to
determine protein concentration was accomplished by utilizing a micro BCA protein assay
kid (ThermoFisher Scientific 23235). The series of standards was made using a
micropipette to transfer set volumes of 2 mg/mL bovine serum albumin (BSA) and distilled
deionized (dd) water into eight separate 0.5 mL tubes (shown in table 1). Tubes A and B
were produced first by creating two diluted BSA solutions with concentrations of 40μg/mL
and 30μg/mL respectively. Thereafter, diluted BSA solutions of concentrations (μg/mL) of
20, 15, 10, 7.5, 5, and 0 were made by transferring 150 μL of the respective BSA solution
to the next ordered tube that would result in a BSA solution of half that concentration (tubes
B through J).
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Table 1. Micro BCA protein concentration standards prepared for protein concentrations
assay (BSA standard at 2mg/mL)

Tube

dd H2O added

BSA vol added

Final Concentration

A

490 μL

10 μL

40 μg/mL

B

394 μL

6 μL

30 μg/mL

C

150 μL

150 μL from

20 μg/mL

dilution A
D

150 μL

150 μL from

15 μg/mL

dilution B
E

150 μL

150 μL from

10 μg/mL

dilution C
F

150 μL

150 μL from

7.5 μg/mL

dilution D
G

150 μL

150 μL from

5 μg/mL

dilution E
H

150 μL

0 μL

0 μg/mL

Following the production of the standards, an array of protein concentrations was
made in eight separate tubes by using diluted NE and CE samples. By using the BoM
cellular extracts, (Phen+NE, PUG+NE, Phen+CE, and PUG+CE) dilutions were prepared
for placement in a 96-well plate. The NEs and CEs were then made into two different
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dilutions resulting in eight total solutions. Four different 1:40 dilutions were produced by
diluting the sample in tubes. Each 1:40 dilution that was produced was composed of 2.5
μL of protein sample and 97.5 μL of dd water respective to 100 μL. The dilutions were
then pipetted into different wells on the plate. From the corresponding tubes of 1:40
dilution solutions, four 1:80 dilutions were produced by adding 50 μL of the 1:40 dilutions
to 50 μL of dd water in separate tubes. These dilutions consisted of column 11 on the well
plate shown on table 2. Filling column 12 of the 96-well plate was completed by transfer
and dilution of the respective NE or CE extracts in column 11. Following production of the
array of protein concentrations, 100 μL of each standard was added to individual wells on
column 10 of a 96-well plate.
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Table 2. BoM cell BCA protein concentration assay: 96-well plate layout
10

11

12

A

0 μg/mL
(100μL)

Phen NE
(1:40)

Phen NE
(1:100)

B

5 μg/mL
(100μL)

Phen CE
(1:40)

Phen CE
(1:100)

C

7.5 μg/mL
(100μL)

PUGNAc NE
(1:40)

PUGNAc NE
(1:100)

D

10 μg/mL
(100μL)

PUGNAc CE
(1:40)

PUGNAc CE
(1:100)

E

15 μg/mL
(100μL)

Phen NE
(1:80)

Phen NE
(1:100)

F

20 μg/mL
(100μL)

Phen CE
(1:80)

Phen CE
(1:100)

G

30 μg/mL
(100μL)

PUGNAc NE
(1:80)

PUGNAc NE
(1:100)

H

40 μg/mL
(100μL)

PUGNAc CE
(1:80)

PUGNAc CE
(1:100)

A working solution was then prepared by mixing 36 μL of BCA reagent C, 864 μL
of BCA reagent B, and 900 μL of BCA reagent A (1:24:25 ratio), of which 100 μL was
added to each well and mixed well. After preparation of the three columns on the 96-well
plate, the plate was incubated at 37 °C for two hours. Following this two-hour period, the
plate was then analyzed using the SPECTRAFluor Plus and read at 562nm.
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Coupling of the HIF antibody to the resin
The purpose of using immunoprecipitation (IP) was to isolate and purify the HIF1α protein so that it may be used for mass spectroscopy. Preparation for IP began with
cross linking the primary anti-HIF-1α antibody (BD Transduction Laboratories: cat:
610959, Lot: 06820, 250 μg/mL) to the protein A/G agarose bead using a commercial kit
(Pierce, cat: 26147).
A 2 mL of 1x coupling buffer was made by diluting 100 μL of 20x of coupling
buffer with 1900 μL of water (QIAGEN 1017879). The Pierce Protein A/G Plus Agarose
(20 μL) was then placed into a Pierce spin column and centrifuged at 1000 x g for one
minute. The prepared Coupling Buffer was then used to wash the resin and centrifuged
once more. Following this step, 10 μg of antibody for coupling was made by preparing 10
μL of antibody (Ab), 5 μL of 20 x Coupling Buffer, and 85 μL of dd water. The prepared
solution was then added to the column containing the resin.
Preparation for the crosslinking of the antibody began with adding 217 μL dimethyl
sulfoxide (DMSO) to 25 mM disuccinimidyl suberate (DSS) to make a 1:10 dilute solution
of 2.5mM DSS. Following, 2.5 μL of 20x Coupling Buffer, 9 μL of 2.5 mM DSS, and 38.5
μL of distilled deionized (dd) water was added to the column to initiate the coupling
reaction and incubated for 50 minutes on a rotator. Once reacted, 50 μL of elution buffer
was used to wash the solution twice to remove any non-crosslinked antibodies and halt the
reaction. This solution was then washed twice with 200 μL of cold IP Lysis/Wash Buffer
and centrifuged after each washing. The final product of this procedure was then used in
the IP process to isolate the purified HIF-1α protein.
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Immunoprecipitation
In preparation of IP, 330 μL of Phen treated BoM cell NE and 295 μL of PUGNAc
(referred to as PUG in this procedure) treated BoM NE were washed with IP Lysis (170
μL and 205 μL, respectively to make volume consistent). Both of the extracts were then
incubated overnight at 4 °C. Following incubation, the extracts were placed in separate
columns, the bottom plug was removed, and the screw cap was removed. The columns
were then placed in a collection tube and centrifuged for one minute at 1000 x g; the flow
through was saved (Phen elute 1 and PUG elute). Following this step, 200 μL of lysis wash
was added and rotated once more, twice. Next, 100 μL of 1x conditioning buffer (2.15 μL
100x and 212.85 μL dd water) was used to wash the samples before placement into new
tubes with 10 μL of elution buffer before centrifugation at 1000 x g for five minutes. After
spinning, 50 μL of elution buffer was added once more before another five minutes of
rocking.
Following removal from the centrifuge, the “elute” from each extract was
transferred to a new tube and stored on ice (Phen elute 2 and PUG elute 2). The columns
were then regenerated with 100 μL of 1x coupling buffer, and rotated, which was repeated
once. A new bottom plug was then used, and the bottom was wrapped up after 250 μL of
1x coupling buffer was added to each column. The sample was then put into 15 mL tubes
and stored at 4 °C (Phen NE and PUG NE). The products obtained from this procedure
were then prepared for separation by SDS-PAGE and are as followed: Phen NE, Phen elute
1, Phen Elute 2, PUG NE, and PUG elute 2. These samples, a molecular weight marker
(Bio-Rad, Kleidoscope, 161-0324 (discontinued)), and the “Ab” Phen, “Ab PUG” were
then prepared for loading onto the gel. The last two lanes on the right of the SDS page were
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filled with the left-over pellet from the columns. In lane nine and lane ten, 4 μL of 5x
sample buffer and 16 μL of sample of Phen and PUG were added, respectively (not shown
in table 3). These solutions were mixed and then boiled for five minutes to denature
proteins. After, the samples were put on ice and the sample was collected through a quick
spin.

Table 3. Layout for SDS-PAGE sample preparation
Lane
number

1

2

3

4

5

6

7

8

Sample
type

Mw

Phen NE

Phen
Elute1

Phen
Elute2

PUG
NE

PUG
Elute

“Ab”
Phen

“Ab”
PUG

5x
Sample
Buffer
(μL)

4

4

4

4

4

4

4

4

Sample
(μL)

10

15

3

3

15

3

16

16

dd H2O
(μL)

6

13

13

13

SDS-PAGE and Western Blot
The samples prepared from the IP procedure were loaded onto a Bio-Rad precast
gel (Mini-protean TGX, 4-20%, 456-1094) (order shown on table 3). A 1x Tris/
tricine/SDS buffer, prepared by diluting the 10x buffer solution (Bio-Rad 161-0744) with
180 mL of dd water, was then added to the electrophoresis apparatus. The molecular weight
marker was then loaded into the first lane, followed by the loading of samples (left to right
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in table 3) in the rest of the gel lanes respectively. The gel was run at 125 V for 45 minutes,
then transferred from the SDS-PAGE gel to a dd water prewet nitrocellulose membrane.
This was achieved by soaking the gel in 1x transfer buffer, composed of 100 mL of 10x
TG (Bio-Rad 161-077), 100 mL of methanol (HPLC Grade, Fisher A 452-4), and 800 mL
of dd water, the transfer sandwich assembled, and for 50 minutes at 140 mA. An ice pack
was placed outside the apparatus to assist with temperature control. The transfer apparatus
was placed on a stir plate with a stir bar to aid in solution mixing. After transfer, Ponceau
S. Solution (Sigma Aldrich) was used to stain the proteins on the nitrocellulose membrane
to ensure the transfer is effective
For Western blot, a Tween-Tris buffered solution (TTBS) was prepared by diluting
0.25 mL of tween 20 (Sigma Aldrich, P1379) and 50 mL of 10x Tris Buffered Saline
(Boston Bioproducts, BM-301) with 450 mL of dd water. The blocking solution was
prepared by dissolving 4.8g of non-fat dry milk (blotting-grade blocker, Bio-Rad 1706404) into 96 mL of TTBS. The membrane was incubated with the 5% non-fat dry milk
TTBS solution for an hour with rocking at room temperature, to prevent non-specific
antibody binding to the membrane. The membrane was then washed twice with TTBS (5
minutes each, rocking, room temperature). Following the washes, the primary HIF-1α
antibody (BD Transduction Laboratories: cat: 610959, Lot: 06820, 250 μg/mL) was added
at the dilution of 1:1000 in the blocking solution and the incubation continued for another
hour. The membrane was then washed twice with 5% non-fat milk/TTBS solution (5
minutes each, rocking, room temperature). The secondary antibody, a stabilized goat-antimouse HRP-conjugated antibody (PIERCE, cat: 1858413, Lot: HH 10648, 10 μg/mL) was
added to the blocking solution at 1:3000 dilution (3 μL to 9 mL of 5% milk/TTBS). After
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an hour, the membrane was washed once for 10 minutes with TTBS followed by two
washes for 5 minutes each with TTBS. The membrane was then developed with West
Femto Maximum Sensitivity Substrate (Thermo 430951) and imaged on a Bio-Rad
ChemiDoc™ Imaging System.
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Results/Discussion
Previous research from our group has established the conditions that induced the
O-GlcNAcylation of HIF-1α protein in breast cancer cells. To further investigate the role
of this PTM in HIF biology and oxygen homeostasis, it is important to identify the amino
acid residue(s) that is/are subjected to this modification. A combined approach that
incorporates cell biology and mass spectrometry was applied to isolate HIF-1α protein and
identify the O-GlcNAcylated site(s). Following treatment with 1,10-phenanthroline and
PUGNAc, nuclear, and cytoplasmic extract samples were prepared from BoM cells and the
protein concentrations were determined by the BCA method. The following table was
acquired from the SPECTRAFluor Plus, a fully automatic, computer-controlled
fluorescence, absorbance and luminescence instrument used to analyze microplate
samples. The values obtained are characterized by light absorbance measured at 562 nm.
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Table 4. Light absorption in 562 nm of micro BCA protein concentration assay of BoM
nuclear and cytoplasmic extracts.
10

11

12

A

0.104

1.985

0.347

B

0.183

0.747

0.269

C

0.207

1.895

0.527

D

0.240

0.639

0.296

E

0.310

0.239

0.401

F

0.380

0.37

0.362

G

0.562

0.696

0.378

H

0.583

0.546

0.060

By using a line of best fit, derived from the slope of the standard values, the protein
concentrations of nuclear extracts and cytoplasmic extracts were determined:
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Figure 1. Standard curve from micro BCA protein concentration assay of BoM nuclear and
cytoplasmic extracts.

A line of best fit, that was determined from the standard curve, had the linear
formula y = 0.0668x - 0.0876; The x and y value represent the protein concentration and
absorbance respectively. The formula was then used to calculate the protein concentration
from the respective absorption data. These values that correspond with their dilution, either
1:40 or 1:80, were then multiplied by 40 and 80 to obtain the original protein concentration.
The same method was used for the 1:100 dilutions. Protein concentration values obtained
from the standard curve linear trendline equation are shown in table 5 and correspond with
the data in Table 2 and Table 4.
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Table 5. Protein concentration calculated using the standard curve trendline equation (y =
0.0668x - 0.0876).
10

11

12

A

1.311

-

4.949

B

2.494

-

3.781

C

2.853

-

7.644

D

3.347

-

4.186

E

4.395

3.332

5.575

F

5.443

5.293

5.174

G

8.167

-

5.413

H

-

7.928

0.653

Protein concentration values that correspond with absorbances above 0.583 nm (40
μg/mL) were not utilized in data calculation. This is because the extrapolate will be
unreliable. This data indicates that nuclear extracts of both Phen and PUGNAc treated BoM
cells contain higher concentration levels of HIF-1α protein compared to the cytoplasmic
extracts. However, another separate protein concentration assay should be conducted in
order to confirm concentration values to ensure that they are reliable.
To enhance the purity of HIF-1α protein from the immunoprecipitation, the antiHIF-1α antibody was conjugated to the protein A/G beads by crosslinking using a
commercial kit. The HIF-1α protein isolated from the IP procedure was analyzed by
Western blot. Both the nuclear extract samples and the elutes from the columns were
subjected to SDS-PAGE separation followed by Western blot.
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Figure 2. Western blot analysis of HIF-1α in nuclear and cytoplasmic extracts

The molecular weight marker was loaded into lane one, and no band appeared
because the marker does not contain HIF-1α proteins. Lanes two through four contained
the Phen NE, the first Phen NE elute, and the second Phen NE elute, followed by PUG NE
and PUG Elute into lanes five and six, Phen “Ab” and PUG “Ab” into lanes seven and
eight, and finally Phen o/n and PUG o/n into the nine and ten lanes. After visualization, it
was determined that the results from the Western Blot Analysis of HIF-1α were not as
expected. Specifically, we were not able to purify HIF-1α protein in this effort.
The appearance of the bands shown in the elute lanes indicated the presence of
antibodies. Ineffective conjugation of the antibody to the protein A/G agarose bead would
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result in the separation of non-crosslinked HIF-1α antibody from the column after
centrifugation. This could also indicate that there is an absence of the HIF-1α protein in the
lane, which could be accounted to the failed antibody conjugation to the bead. This could
also be why the IP lanes do not have much protein. The longer bands shown on the Western
blot may have been caused by degradation of the HIF-1α protein. If HIF-1α was degraded,
then antibodies would not be able to interact with the protein and no distinct bands would
appear. The weak bands may also appear because the crosslinking of antibody to column
was not effective and some of the antibody might not have been bound or were detached.
The BoM cells were treated with PUGNAc in order to raise O-GlcNAc levels. In
addition, treatment of BoM cells with 1,10-phenanthroline was used as a control to ensure
the induction of HIF-1α protein. Both treatments of the NE samples were expected to
present HIF-1α bands in the Western blot. If the procedure had produced the results
expected, mass spectroscopy would be utilized in order to analyze HIF-1α protein samples
to detect O-GlcNAcylation. Even though the first round of this experiment did not turn out
as expected, it has laid a foundation for continuation of the project.
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Conclusion and Future Perspective
There are many anticancer drugs that are aimed at specific molecular targets
responsible for, in one way or another, enabling particular capabilities. However, targeting
one key pathway may not completely disable a hallmark ability, allowing for the possibility
of some cancer cells to survive and eventually adapt to the pressure applied by therapeutic
measures. This ultimately sheds a light on the importance of exploring the therapeutic
targeting of specific biomolecules that influence multiple hallmarks of cancer. Specifically,
the HIF-1α protein subunit, has key roles in the acquisition of multiple hallmark abilities
that promote cancer development and survival. As these subunits increase in concentration
in cancer cells, more heterodimeric HIFs form, which induces transcriptional activity that
allows for metabolic reprogramming, and promotes other hallmarks including, resisting
cell death, angiogenesis, and invasion and metastasis. Having a primary effect on the
intracellular regulation of HIF-1α in breast cancer cells, O-GlcNAcylation, which stabilizes
the protein subunit and allows for maintenance of its transcriptional effects, has been
correlated to negative prognoses in these patients. The implications that the process of OGlcNAcylation has on the regulation of HIF-1α and outcomes of breast cancer patients has
drawn attention to exploration of therapeutic targeting. Although the results were not as
expected, the completion of this specific procedure for the first time in hopes of
establishing usable samples for mass spectroscopy has laid a basis for future endeavors
regarding the detection of O-GlcNAcylation in HIF-1α proteins.

36

Bibliography
American Cancer Society | Cancer Facts & Statistics. (n.d.). Retrieved March 12, 2019,
from https://cancerstatisticscenter.cancer.org/#!/cancer-site/Breast
Breast cancer. (2019, January 10). Retrieved March 10, 2019, from
https://www.mayoclinic.org/diseases-conditions/breast-cancer/diagnosistreatment/drc-20352475
Breast Cancer Statistics. (2018, September 07). Retrieved March 12, 2019, from
https://www.bcrf.org/breast-cancer-statistics
Cancer
Classification.
(n.d.).
Retrieved
March
10,
2019,
from
https://training.seer.cancer.gov/disease/categories/classification.html
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015).
New horizons in tumor microenvironment biology: challenges and
opportunities. BMC Medicine, 13, 45. doi:10.1186/s12916-015-0278-7
DeBerardinis, R. J., &, Chandel, N. S. (2016). Fundamentals of cancer metabolism.
Science Advances, 2(5), e1600200. http://doi.org/10.1126/sciadv.1600200
Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G.,
Mukherjee, C., Shi, Y., Gélinas, C., Fan, Y., Nelson, D. A., Jin, S., & White, E.
(2006). Autophagy promotes tumor cell survival and restricts necrosis,
inflammation, and tumorigenesis. Cancer Cell, 10(1), 51–64.
doi:10.1016/j.ccr.2006.06.001
Exploring cancer proliferative signaling pathways [PDF]. (2015). Thermo fisher
SCIENTIFIC
Inc.
Retrieved
from
https://www.thermofisher.com/content/dam/LifeTech/global/promotions/globa
l/images/aai-2015/aai-pdfs/CancerProliferativePathwaysHandbook-r2.pdf
Ferrer, C. M., Lynch, T. P., Sodi, V. L., Falcone, J. N., Schwab, L. P., Peacock, D. L.,
Vocadlo, D. J., Seagroves, T. N., & Reginato, M. J. (2014). O-GlcNAcylation
regulates cancer metabolism and survival stress signaling via regulation of the
HIF-1
pathway.
Molecular
Cell,
54(5),
820–831.
doi:10.1016/j.molcel.2014.04.026
Gilkes, D. M., & Semenza, G. L. (2013). Role of hypoxia-inducible factors in breast
cancer metastasis. Future oncology (London, England), 9(11), 1623–1636.
doi:10.2217/fon.13.92
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation.
Hallmarks of Cancer: The Next Generation, Cell 144(5), 646-674.
doi:
https://doi.org/10.1016/j.cell.2011.02.013
Kietzmann, T., Mennerich, D., & Dimova, E. Y. (2016). Hypoxia-Inducible Factors
(HIFs) and Phosphorylation: Impact on Stability, Localization, and
Transactivity. Frontiers in Cell and Developmental Biology, 4, 11.
doi:10.3389/fcell.2016.00011
Kang, Y., Siegal, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C.,
Guise, T. A., Massagué, J., (2003). A multigenic program mediating breast
cancer metastasis to bone. Cancer Cell, 3(6), 537-49. doi:
https://doi.org/10.1016/S1535-6108(03)00132-6

Keith, B., Johnson, R. S., & Simon, M. C. (2011). HIF1α and HIF2α: sibling rivalry in
hypoxic tumour growth and progression. Nature Reviews. Cancer, 12(1), 9–22.
doi:10.1038/nrc3183
37

Liu, Z. J., Semenza, G. L., & Zhang, H. F. (2015). Hypoxia-inducible factor 1 and
breast cancer metastasis. Journal of Zhejiang University. Science. B, 16(1), 32–
43. doi:10.1631/jzus.B1400221
Lundgren K, Holm C, Landberg G. (2007). Hypoxia and breast cancer: prognostic and
therapeutic implications. Cellular and Molecular Life Sciences, ;64(24):3233–
3247. doi:10.1007/s00018-007-7390-6.
Ma, J., & Hart, G. W. (2017). Analysis of Protein O-GlcNAcylation by Mass
Spectrometry. Current Protocols in Protein Science, 87, 24.10.1–24.10.16.
doi:10.1002/cpps.24
Ma, J., & Hart, G. W. (2014). O-GlcNAc profiling: from proteins to proteomes.
Clinical Proteomics, 11(1), 8. doi:10.1186/1559-0275-11-8
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015). The role of hypoxia in cancer
progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia
(Auckland, N.Z.), 3, 83–92. doi:10.2147/HP.S93413
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006). Angiogenesis
in Cancer. Vascular Health and Risk Management, 2(3),
213–219.
Overview of Post-Translational Modification. (n.d.). Retrieved April 10, 2019, from
https://www.thermofisher.com/us/en/home/life-science/proteinbiology/protein-biology-learning-center/protein-biology-resourcelibrary/pierce-protein-methods/overview-post-translational-modification.html
Padua, D., Zhang, X. H., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., &
Massagué, J. (2008). TGFbeta primes breast tumors for lung metastasis seeding
through
angiopoietin-like
4.
Cell,
133(1),
66–77.
doi:10.1016/j.cell.2008.01.046
Semenza G. L. (2017). A compendium of proteins that interact with HIF-1α.
Experimental
Cell
Research,
356(2),
128–135.
doi:10.1016/j.yexcr.2017.03.041
Semenza GL. (2012). Hypoxia-inducible factors: mediators of cancer progression and
targets for cancer therapy. Trends Pharmacol Sci.;33(4):207–214. doi:
10.1016/j.tips.2012.01.005.
Semenza G. L. (2015). The hypoxic tumor microenvironment: A driving force for
breast cancer progression. Biochimica et Biophysica acta, 1863(3), 382–391.
doi:10.1016/j.bbamcr.2015.05.036
Soysal S.D., Tzankov A., Muenst S.E. (2015). Role of the tumor microenvironment in
Breast
Cancer.
Pathobiology,
82(3-4),
142-152.
doi:
https://doi.org/10.1159/000430499
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995). Hypoxia-inducible
factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2
tension. Proceedings of the National Academy of Sciences of the United States
of America, 92(12), 5510–5514.
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou,
J., Cao, K., Li, X., Xiong, W., Li, G., Zeng, Z., & Guo, C. (2017). Role of
tumor microenvironment in tumorigenesis. Journal of Cancer, 8(5), 761–773.
http://doi.org/10.7150/jca.17648

38

What Is Breast Cancer? | Breast Cancer Definition. (n.d.). Retrieved March 12, 2019,
from
https://www.cancer.org/cancer/breast-cancer/about/what-is-breastcancer.html
What your breast cancer type means. (2018, November 01). Retrieved March 11, 2019,
from
https://www.mayoclinic.org/diseases-conditions/breast-cancer/indepth/breast-cancer/art-20045654
Zhang, H., Wong, C. C., Wei, H., Gilkes, D. M., Korangath, P., Chaturvedi, P., Schito,
L., Chen, J., Krishnamachary, B., Winnard, P. T. Jr., Raman, V., Zhen, L.,
Mitzner, W. A., Sukumar, S., & Semenza, G. L. (2011). HIF-1-dependent
expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of
hypoxic breast cancer cells to the lungs. Oncogene, 31(14), 1757–1770.
doi:10.1038/onc.2011.365
Zhou, Y. D., Li, J., Du, L., Mahdi, F., Le, T. P., Chen, W. L., Swanson, S. m., Watabe,
K., & Nagle, D. G. (2018). Biochemical and Anti-Triple Negative Metastatic
Breast Tumor Cell Properties of Psammaplins. Marine Drugs, 16(11), 442.
doi:10.3390/md16110442

39

